ProShares Ultra Nasdaq Biotechnology
Fund Name: |
ProShares Ultra Nasdaq Biotechnology |
Issuer: |
ProShares |
Total Net Assets: |
$78,560,000 |
Inception: |
4/7/10 |
Related Index: |
NASDAQ Biotechnology Index |
ETF Category: |
Health - Leveraged |
Expense Ratio: |
0.95 |
|
Net Asset Value: |
$49.10 |
Number of Holdings: |
222 |
Annualized Yield: |
0.00% |
Annualized Distribution: |
NA |
|
Stock |
Weight |
Amount |
Amgen |
6.53% |
$5,129,996 |
Vertex Pharmaceuticals |
6.29% |
$4,941,749 |
Regeneron Pharmaceuticals |
6.17% |
$4,850,042 |
Gilead Sciences |
6.13% |
$4,817,079 |
Astrazeneca Plc-spons Adr |
3.42% |
$2,688,443 |
List of all 217 stocks held by BIB
» |
|
Future |
Weight |
Contracts |
Proqr Therapeutics NV |
0.04% |
10,020 |
|
Buy (3.24 out of 4)
42nd percentile
|
Shares Short |
7,666 |
Chg. from Last Month |
-5,386 |
Shares Outstanding |
1,625,000 |
% of Shares Short |
0.47% |
Days to Cover |
0.2 |
Based on third party short interest data.
|
|
BIB | ProShares Ultra Nasdaq Biotechnology | ETF Channel | www.ETFChannel.com
Copyright © 2010 - 2024, All Rights Reserved
Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use
and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20
minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.